Likewise, DHODH inhibition by IMU-838 or Vidofludimus free acid improved disease outcomes in preclinical models of autoimmune diseases such as colitis [26] and experimental autoimmune encephalomyelitis (EAE) [27]. Here, DHODH is linked to colitis.